Heart Failure and Atrial Fibrillation, Like Fire and Fury

Area of Science:

• Cardiology
• Internal Medicine

Background:

• Heart failure (HF) and atrial fibrillation (AF) are prevalent cardiovascular conditions.
• These comorbidities frequently occur together, significantly impacting patient outcomes and cardiovascular health.
• The prevalence of both HF and AF is rising due to increasing risk factors.

Purpose of the Study:

• To review the current understanding of the epidemiology and pathophysiology of coexisting HF and AF.
• To incorporate landmark trials influencing current clinical guidelines for managing these conditions.
• To focus on clinically relevant aspects, including inflammation's role and emerging therapies.

Main Methods:

• Literature review of epidemiological data and pathophysiological mechanisms.
• Analysis of landmark clinical trials impacting current guidelines.
• Exploration of recent advancements in treatment modalities.

Main Results:

• Inflammation plays a significant role in the pathophysiology of both AF and HF.
• Catheter ablation is an emerging therapy for heart failure with reduced ejection fraction (HFrEF).
• Biventricular pacing in cardiac resynchronization therapy (CRT) has specific indications.

Conclusions:

• Current guideline-directed therapies are evolving based on recent randomized controlled trials.
• Practice models and national recommendations for managing HF and AF comorbidities are likely to change.
• Understanding the interplay between HF and AF is crucial for optimizing patient care.